Technical Analysis for MRKR - Marker Therapeutics, Inc.

Grade Last Price % Change Price Change
F 2.1 -4.11% -0.09
MRKR closed down 4.11 percent on Tuesday, July 27, 2021, on 81 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Aug 9
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical MRKR trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish -4.11%
Wide Bands Range Expansion -4.11%
Down 3 Days in a Row Weakness -4.11%
Oversold Stochastic Weakness -4.11%
200 DMA Support Bullish -4.98%
Wide Bands Range Expansion -4.98%
Older End-of-Day Signals for MRKR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 8 hours ago
Down 3% about 8 hours ago
Down 2 % about 8 hours ago
Down 1% about 8 hours ago
Fell Below Previous Day's Low about 8 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Marker Therapeutics, Inc. Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Immune System Immunotherapy Treatment Of Cancer Oncology Cancer Immunotherapy Cancer Treatments Virotherapy Ovarian Cancer Tumor Immunotherapies Cell Therapy Her2 Hematological Malignancies Solid Tumor Her2/Neu T Cell Tumor Cell Ovarian Cancers Breast And Ovarian Cancer Tpi

Is MRKR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.77
52 Week Low 1.32
Average Volume 1,166,700
200-Day Moving Average 2.20
50-Day Moving Average 2.79
20-Day Moving Average 2.47
10-Day Moving Average 2.24
Average True Range 0.15
ADX 35.69
+DI 10.54
-DI 32.01
Chandelier Exit (Long, 3 ATRs) 2.80
Chandelier Exit (Short, 3 ATRs) 2.52
Upper Bollinger Bands 3.00
Lower Bollinger Band 1.93
Percent B (%b) 0.16
BandWidth 43.09
MACD Line -0.20
MACD Signal Line -0.17
MACD Histogram -0.0242
Fundamentals Value
Market Cap 100.85 Million
Num Shares 48 Million
EPS -4.17
Price-to-Earnings (P/E) Ratio -0.50
Price-to-Sales 119.19
Price-to-Book 2.75
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.24
Resistance 3 (R3) 2.24 2.21 2.21
Resistance 2 (R2) 2.21 2.17 2.20 2.20
Resistance 1 (R1) 2.15 2.15 2.14 2.15 2.20
Pivot Point 2.12 2.12 2.11 2.11 2.12
Support 1 (S1) 2.06 2.08 2.05 2.06 2.00
Support 2 (S2) 2.03 2.06 2.02 2.00
Support 3 (S3) 1.97 2.03 1.99
Support 4 (S4) 1.97